Last year we had the honour of winning the Vodafone Foundation prize for the best ICT Social Solution in the 12th edition.

Thanks to this recognition we have been able to attend the 2019 edition of Mobile Word Congress integrated in Vodafone’s stand and sharing space with one of the most innovative and important companies in the telecom sector. For us it has been a pleasure to share these days with incredible people from Vodafone such as Mari Satur, Estíbaliz, Gloria or Remedios, who have helped us to make our experience a success. In these 4 days we have been able to share experiences with great projects such as Showleap or Entamar.

And most importantly, we have achieved our goal. To make it visible, raise awareness and try to fight to eliminate the stigma that people with epilepsy still suffer today. Different political personalities, from entities such as the International Red Cross, and the media have passed through our stand and have learnt how our project works to improve the lives of people suffering from this condition.

“Different actors of the medical,

investment and technological

sectors have shown their 

interest in helping us”

We have also had an agenda full of meetings with different actors of the medical, investment and technological sectors that have shown their interest in helping us to make our device to assess the risk of epileptic seizure a reality in the shortest possible time.

And finally, we won the #IOTInnovationCatalan prize organized by #IOTWTIWC at  @4YfN, where our colleague Jordina gave an excellent presentation.

In short, it has been an incredible experience that encourages us to continue pushing our project forward.

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.